mAb Combo Therapy Safe to Treat Advanced Cancers

In an early-phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and antitumor activity in individuals with various types of advanced cancer. The findings are published in the American Cancer Society’s Cancer.

Both medications tested in the trial support immune responses against tumor cells. CS1002 increases the activation and proliferation of T cells by binding to a T-cell receptor called CTLA-4. CS1003, also called nofazinlimab, blocks the programmed cell death protein 1 (PD-1) that is expressed on various types of immune cells and plays a role in suppressing the immune system.

In this first-in-human, multicenter, open-label study conducted from April 26, 2018, to January 18, 2022, at nine study sites in Australia and China, Phase 1a involved monotherapy dose-escalation (Part 1), which was followed by Phase 1b combination therapy dose escalation (Part 2) and expansion (Part 3). Various dosing schedules of CS1002 (0.3, 1, or 3 mg/kg once every three weeks, or 3 mg/kg once every nine weeks) were evaluated with 200 mg CS1003 once every three weeks.

Parts 1, 2, and 3 of the trial included 13, 18, and 61 patients, respectively, who had advanced/metastatic solid, relapsed, or refractory tumors. During treatment, investigators did not observe any dose-limiting toxicities or a maximum tolerated dose. 

Side effects of the combination therapy

Treatment-related side effects such as diarrhea, fatigue, and rash were reported in 30.8 percent, 83.3 percent, and 75.0 percent of patients in Parts 1, 2, and 3, respectively. Serious side effects such as intestinal inflammation and severe skin reactions were experienced by 15.4 percent, 50.0 percent, and 18.3 percent of patients in each part.

Of 61 patients evaluated for treatment efficacy, 23 (37.7 percent) with different types of tumors experienced a positive response. Higher response rates occurred with conventional and high-dose CS1002 regimens (1 mg/kg once every three weeks or 3 mg/kg once every nine weeks) compared with low-dose CS1002 (0.3 mg/kg once every three weeks) in certain cancers like melanoma.

“CS1002 in combination with CS1003 had manageable safety profile across a broad dosing range and showed promising antitumor activities across CS1002 dose levels when combined with CS1003,” the investigators wrote. “This supports further assessment of CS1002 in combination with CS1003 for the treatment of solid tumors.”

- This press release was originally published on the Wiley website